1stOncology™: Cancer Intelligence Service – Page 8370 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences

On September 29, 2021 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported that it is scheduled to participate in the following upcoming events (Press release, Arrowhead Pharmaceuticals, SEP 29, 2021, View Source [SID1234590470]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Chardan’s 5th Annual Genetic Medicines Conference – October 4-5, 2021

October 4, 2021, 4:30 p.m. ET – Vince Anzalone, CFA, Arrowhead’s vice president of investor relations, will participate in a fireside chat presentation

H.C. Wainwright 5th Annual NASH Investor Conference – October 12, 2021

October 12, 2021 – James Hamilton, M.D., MBA, Arrowhead’s senior vice president of discovery and translational medicine will participate in a fireside chat presentation

A copy of the presentation materials and/or live webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

Fusion Pharmaceuticals Appoints Mohit Rawat as President and Chief Business Officer

On September 29, 2021 Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, reported the appointment of Mohit Rawat as President and Chief Business Officer (Press release, Fusion Pharmaceuticals, SEP 29, 2021, View Source [SID1234590467]). Mr. Rawat brings to Fusion more than 15 years of experience in the biopharmaceutical industry, with expertise in corporate strategy, business development and commercial execution, including product development, launch planning and commercialization.

"We are delighted to welcome Mohit to Fusion during a period of rapid growth for the Company, with plans to have a third program in the clinic by the middle of 2022, and in a time of expanding interest in radiopharmaceuticals as precision medicines," said Chief Executive Officer John Valliant, Ph.D. "We have used our platform and partnerships to build a deep pipeline of targeted alpha therapies with an emphasis on creating differentiated radiopharmaceuticals. As we progress, we look forward to leveraging Mohit’s corporate strategy, business development, and commercial leadership experience acquired from his previous positions at multiple large pharmaceutical companies. Mohit will focus on advancing Fusion’s agenda by capitalizing on our efforts to create first-in class radiopharmaceuticals and establish global strategic partnerships while planning ahead for pipeline and commercial success."

Mr. Rawat was most recently vice president and global disease lead for the $3 billion CML franchise (including asciminib/ABL001 and TASIGNA) at Novartis Oncology where he helped bring forward for approval and potential blockbuster success the FDA-designated priority review STAMP inhibitor asciminib. Prior to this role, he was the U.S. marketing director for COSENTYX, where he led multiple commercial and strategic efforts for Novartis’ top product with more than $4 billion in sales; and executive director, early-stage pipeline, for NASH, cardiovascular, renal and metabolism, also at Novartis. Before joining Novartis, Mr. Rawat was asset team lead, senior director, immunology and neuroscience at AbbVie Pharmaceuticals. Prior to that, he was with McKinsey and Company, where he was a leader in the biopharmaceutical practice and led client teams on business development, research and development, product commercialization and strategy projects. Earlier in his career, Mr. Rawat held several positions of increasing responsibility within Novartis Pharmaceuticals, across marketing and sales, drug development and portfolio planning.

Mr. Rawat holds an M.B.A. from Harvard Business School, an M.S. in chemical engineering from Massachusetts Institute of Technology (MIT), a certificate in finance from Sloane School of Management at MIT, and M. Tech. and B. Tech. degrees in chemical engineering from Indian Institute of Technology (IIT).

Inducement Equity Awards

Fusion’s Compensation Committee of the Board of Directors approved a grant of stock options to Mr. Rawat to purchase 257,000 of Fusion’s common shares. Each option was granted as an inducement equity award outside Fusion’s 2020 Stock Option and Incentive Plan and was made as an inducement material to Mr. Rawat’s acceptance of employment with Fusion. The options have an exercise price of $8.26 per share, which is equal to the closing price of Fusion’s common stock on September 27, 2021. Each option has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the grant date and then in equal monthly installments for 36 months thereafter, subject to Mr. Rawat’s continued service with Fusion through the applicable vesting dates.

Third ADC with Synaffix’s Technology Enters Clinical Development

On September 29, 2021 Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, reported that its partner Shanghai Miracogen has commenced a Phase I trial in the US with MRG004A, an ADC designed to treat solid tumors (Press release, Synaffix, SEP 29, 2021, View Source [SID1234590466]). This is the 3rd ADC built with GlycoConnect ADC technology to enter the clinic.

Synaffix signed a licensing agreement with Shanghai Miracogen (now fully owned by LEPU BIOPHARMA CO., LTD), a Chinese biotechnology company with a clinical-stage pipeline of ADCs, in 2019. This major development has triggered a milestone payment to Synaffix.

MRG004A is an ADC targeting human Tissue Factor (TF), conjugated using GlycoConnect site specific conjugation technology. In preclinical studies, MRG004A exhibited significantly improved stability in circulation, enhanced efficacy and tolerability compared to the conventional ADC technology.

Mary Hu, CEO of Miracogen and Co-CEO of Lepu Biopharma said:

"We have been very pleased with our collaboration with Synaffix and the data that we generated with ADCs built with its outstanding ADC technology. MRG004A has demonstrated the potential to become a best-in-class TF-targeted ADC and to address high unmet medical need for patients."

Peter van de Sande, CEO of Synaffix, said:

"This is an important milestone in our collaboration and we look forward to continuing our successful partnership as Miracogen develops multiple best-in-class ADC product candidates using our technology.

There are now 3 ADCs that were built with Synaffix’s ADC technology in clinical development. We have now announced 6 collaborations that we have established with biotech and pharma partners around the world and more than 10 ADCs are being developed under those license agreements. We look forward to announcing further progress and additional partnerships in the coming months."

In the last few months, Synaffix has signed significant agreements with Kyowa Kirin, a global specialty pharmaceutical company; ProfoundBio, an emerging oncology biotherapeutics company; and Innovent Biologics, a leading biopharmaceutical company developing innovative medicines for the treatment of major diseases. These come in addition to preexisting collaborations with ADC Therapeutics, Mersana Therapeutics and Shanghai Miracogen.

Reference to SRA737 Timeline at Cantor Conference

On September 29, 2021 Sareum Holdings plc (AIM: SAR), the specialist drug development company, reported that Sierra Oncology, the licence holder for SRA737 (a novel Chk1 inhibitor), presented at 21.00 BST on 28 September at the 2021 Cantor Virtual Global Healthcare Conference in a Fireside Chat. During this conference and included in a slide of recent and upcoming milestones, Sierra Oncology’s CEO, Stephen Dilly, referred to the initiation of additional clinical studies with pipeline agents including SRA737 in other haematologic and solid tumour indications in the first half of 2022 (Press release, Sareum, SEP 29, 2021, View Source [SID1234590465]).

Specifically, reference was made to a potential role for SRA737 in combination studies in solid tumours, including pancreatic cancer, where patients have become resistant to PARP inhibitors.

In a previous discussion, noted by Sareum on 6 August 2021, of the rationale for in-licensing BET inhibitor AZD5153, now known as SRA515, from AstraZeneca, Sierra referred to possible pipeline expansion opportunities in other haematologic or solid tumour indications. These included potential combinations with SRA737, immune-oncology agents, PARP inhibitors and drugs with other mechanisms of action. Sierra has also noted that SRA515 has shown preclinical efficacy in combination with a diverse range of agents, and that synergy between SRA515 and a family of DNA damage response agents, known as ATR inhibitors, suggested potential utility in combination with SRA737.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed to Sierra in September 2016.

Sareum’s CEO, Dr Tim Mitchell, commented:

"This timeline for the possible initiation of combination studies by Sierra including SRA737 in the first half of 2022 is very encouraging and would represent a significant advance in the development of the SRA737 programme. We look forward to further updates on the clinical development of SRA737, a molecule that has shown great promise in clinical trials and preclinical studies, particularly in combination with other types of cancer therapy,"

Quest Diagnostics To Release Third Quarter 2021 Financial Results On October 21

On September 29, 2021 Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, reported that it will report third quarter 2021 financial results on Thursday, October 21, 2021, before the market opens (Press release, Quest Diagnostics, SEP 29, 2021, View Source [SID1234590464]). It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.

The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.QuestDiagnostics.com/investor. The company suggests participants dial in approximately 10 minutes before the call.

A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 866-360-7722 for domestic callers or 203-369-0174 for international callers; no passcode is required. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on October 21, 2021 until midnight Eastern Time on November 4, 2021.

Anyone listening to the call is encouraged to read the company’s periodic reports on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.